Robert F. Kennedy Jr., nominated to be health secretary, seemed unfamiliar with the particulars of the massive insurance ...

Despite high demand for an option like Journavx, doctors fear the drug’s price could be a major hangup for insurers, ...

The testing company ended last year with $79 million and told investors it will need to raise money to fund its operations ...

Pharmaceutical executives are near unanimous (with 68% strongly agreeing and 31% somewhat agreeing) in their concern about a marked increase in theft, fraud, and/or attacks in the pharmaceutical ...

The FDA clearance aids AstraZeneca and Daiichi Sankyo’s plan to position ADCs like Enhertu ahead of chemotherapy in a variety ...

At a Senate hearing, Kennedy also said the president has directed him to examine the well-established safety of mifepristone, ...

Julie Kim, currently Takeda’s U.S. head, will replace Weber in June 2026 and become one of the few female CEOs of a top drugmaker.